Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
OwnerMary Faris, Rene S. Hubert +5inventors
InventorsMary Faris, Rene S. Hubert, Arthur B. Raitano, Daniel E. H. Afar, Elana Levin, Pia Challita-Eid, Aya Jakobovits
Life of this patent
Estimating the term…
Abstract
A novel gene (designated 158P1D7) and its encoded protein are described. While 158P1D7 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 158P1D7 provides a diagnostic and/or therapeutic target for cancers,. The 158P1D7 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.
Claims66
A method for monitoring 158P1D7 gene products in a biological sample from a patient who has or who is suspected of having cancer, the method comprising:
- determining the status of 158P1D7 gene products expressed by cells in a tissue sample from an individual;
- comparing the status so determined to the status of 158P1D7 gene products in a corresponding normal sample;
- and,
- identifying the presence of aberrant 158P1D7 gene products in the sample relative to the normal sample.
A composition comprising:
- a substance that modulates the status of 158P1D7 or a molecule that is modulated by 158P1D7 and thereby modulates the status of a cell that expresses 158P1D7.
A method of generating a mammalian immune response directed to 158P1D7, the method comprising:
- exposing cells of the mammal's immune system to an immunogenic portion of an 158P1D7-related protein or a nucleotide sequence that encodes said protein, whereby an immune response is generated to 158P1D7.
A method of delivering a cytotoxic agent to a cell that expresses 158P1D7, said method comprising:
- providing a cytotoxic agent conjugated to an antibody or fragment thereof that specifically binds to 158P1D7;
- and,
- exposing the cell to the antibody-agent conjugate.
A method of inducing an immune response to a 158P1D7 protein, said method comprising:
- providing a 158P1D7-related protein that comprises at least one T cell or at least one B cell epitope;
- contacting the epitope with an immune system T cell or B cell respectively, whereby the immune system T cell or B cell is induced.
An antibody or fragment thereof that specifically binds to a 158P1D7-related protein.
An assay for detecting the presence of a 158P1D7-related protein or polynucleotide in a biological sample from a patient who has or who is suspected of having cancer, comprising steps of:
- contacting the sample with an antibody or another polynucleotide, respectively, that specifically binds to the 158P1D7-related protein or polynucleotide, respectively;
- and,
- determining that there is a complex of the antibody and 158P1D7-related protein or the another polynucleotide and 158P1D7-related polynucleotide.
An assay for detecting the presence of 158P1D7 mRNA in a biological sample from a patient who has or who is suspected of having cancer, said method comprising:
- (a) producing cDNA from the sample by reverse transcription using at least one primer;
- (b) amplifying the cDNA so produced using 158P1D7 polynucleotides as sense and antisense primers, wherein the 158P1D7 polynucleotides used as the sense and antisense primers are capable of amplifying the 158P1D7 cDNA contained within the plasmid as deposited with American Type Culture Collection as Accession No. (to be assigned);
- and
- (c) detecting the presence of the amplified 158P1D7 cDNA.
A composition comprising a polynucleotide from position number 23 through number 2548 of SEQ ID NO.:
- 656.
A composition comprising SEQ ID NO.:
- 656.
A composition comprising a polynucleotide that encodes an 158P1D7-related protein that is at least 90% homologous to the entire amino acid sequence shown in SEQ ID NO.:
- 657.
An analog peptide of eight, nine ten or eleven contiguous amino acids of SEQ ID NO.:
- 657
A composition comprising a polynucleotide that encodes at least one peptide set forth in Tables V-XVIII.
A composition comprising a polynucleotide that encodes a peptide region of at least 5 amino acids of SEQ ID NO.:
- 657 in any whole number increment up to 841 that includes an amino acid position selected from:
- an amino acid position having a value greater than 0.5 in the Hydrophilicity profile of FIG. 11, an amino acid position having a value less than 0.5 in the Hydropathicity profile of FIG. 12;
- an amino acid position having a value greater than 0.5 in the Percent Accessible Residues profile of FIG. 13;
- an amino acid position having a value greater than 0.5 in the Average Flexibility profile on FIG. 14;
- or an amino acid position having a value greater than 0.5 in the Beta-turn profile of FIG. 15.
A composition comprising a polynucleotide that encodes a 158P1D7-related protein whose sequence is encoded by the cDNAs contained in the plasmid designated p158P1D7-Turbo/3PX deposited with American Type Culture Collection as Accession No. (to be assigned).
A composition comprising a polypeptide at least 90% homologous to SEQ ID NO.:
- 657.
A composition comprising a CTL polypeptide epitope from SEQ ID NO.:
- 657.
A composition comprising a peptide region of at least 5 amino acids of SEQ ID NO.:
- 657 in any whole number increment up to 841 that includes an amino acid position selected from:
- an amino acid position having a value greater than 0.5 in the Hydrophilicity profile of FIG. 11, an amino acid position having a value less than 0.5 in the Hydropathicity profile of FIG. 12;
- an amino acid position having a value greater than 0.5 in the Percent Accessible Residues profile of FIG. 13;
- an amino acid position having a value greater than 0.5 in the Average Flexibility profile on FIG. 14;
- or an amino acid position having a value greater than 0.5 in the Beta-turn profile of FIG. 15.
A composition comprising a 158P1D7-related protein whose sequence is encoded by the cDNAs contained in the plasmid designated p158P1D7-Turbo/3PX deposited with American Type Culture Collection as Accession No. (to be assigned).
Dependencies are inferred from the claim text.